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Abstract
Background: Available guidelines on the management of upper tract urothelial carcinoma (UTUC) are restricted due to the
lack of strong evidence–based recommendations. Adequate, well-powered randomized trials are missing due to the rarity of the
disease. To overcome this problem, we need alternative study designs to provide generalizable data.
Objective: The primary aim of this registry is to provide a real-world overview on patterns of presentation and management of
UTUC. Secondary objectives include comparison of outcomes of different treatments and tumor stages and evaluation of compliance
with the current European Association of Urology recommendations for UTUC.
Methods: For this observational, international, multicenter, cohort study, clinical data of consecutive patients suspected of
having UTUC, irrespective of type of management, will be prospectively collected up to 5 years after inclusion. Data on the
patterns of presentation, diagnostics, and treatment as well as short-, mid-, and long-term oncological and functional outcomes
will be analyzed. Possible associations between variables, basal characteristics, and outcomes will be tested by multivariable
analyses. The methodology will address potential sources of bias and confounders.
Results: The registry was initiated in November 2014 after obtaining institutional review board approval. Data collection started
in December 2014. At the time of submission of this manuscript, 2451 patients from 125 centers from 37 countries were included.
Inclusion of patients will be closed 5 years after initiation of the registry. Quality checks will be performed centrally with continuous
communication and feedback with the centers to ensure accuracy. The first results are expected in the first trimester of 2020.
Conclusions: This large observational prospective cohort will generate landmark “real-world” data and hypotheses for further
studies. We expect these data to optimize the management of UTUC, provide insights on harms and benefits of treatment, and
serve as quality control.
Trial Registration: ClinicalTrials.gov NCT02281188; https://clinicaltrials.gov/ct2/show/NCT02281188.
International Registered Report Identifier (IRRID): DERR1-10.2196/15363
JMIR Res Protoc 2020 | vol. 9 | iss. 1 | e15363 | p. 1https://www.researchprotocols.org/2020/1/e15363
(page number not for citation purposes)
Baard et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
(JMIR Res Protoc 2020;9(1):e15363) doi: 10.2196/15363
KEYWORDS
upper urinary tract; urothelial cancer; incidence; management; outcomes; registry
Introduction
Background
Upper tract urothelial carcinomas (UTUCs) have a low
prevalence, with an estimated annual incidence of 2 per 100,000
inhabitants in Western countries [1]. Most of them are urothelial
cell carcinomas arising from the lining endoluminal urothelium,
and they represent 5%-10% of all urothelial carcinomas [1]. At
diagnosis, nearly 60% of UTUCs are found to be invasive, a
much higher percentage than the 15%-20% reported for its
sibling tumor in the bladder [1,2]. Although the general genotype
of UTUC is similar to its bladder counterpart, it is different in
its genetic expression and frequency by stage [3-5]. UTUC may
present in a primary isolated form in the upper urinary tract or
secondary form after a primary diagnosis of bladder urothelial
carcinoma. Synchronous upper and lower urinary tract urothelial
carcinoma has been reported in up to 17% of cases [6].
Irrespective of whether it is because of advanced diagnostic
methods utilization, decreased competing death causes, or real
increasing incidence, the rate of invasive UTUC tumors (>pT1)
at diagnosis has been increasing in recent years [1,6]. Metastases
are found in 7% of all patients with UTUCs. The 5-year survival
does not reach 50% for patients with pT2/pT3 UTUCs and is
lower than 10% for pT4 tumors [7,8].
The European Association of Urology (EAU) guidelines
recommend risk stratification of UTUC in low- and high-risk
disease, based on clinical and pathological factors. These include
focality and size of the tumor, presence of high-grade urinary
cytology or high-grade histology on biopsy, imaging
characteristics, and presence of previous radical cystectomy for
bladder cancer or variant histology [1,7]. This risk classification
is intended to drive treatment, and some of these risk factors,
either isolated or integrated, have prognostic implications [7-9].
The gold standard of UTUC remains radical nephroureterectomy
(RNU) with complete bladder cuff excision [10,11]. However,
there is a growing interest in minimally invasive, kidney-sparing
approaches by ureterorenoscopy (URS). This shift in treatment
management is fueled by the development and evolution of
flexible instruments. Indications for kidney-sparing management
are discussed in detail in the current guidelines and should be
considered in patients with low-risk disease [1,7,12]. A
particular challenge during endoscopic management is
appropriate grading and staging of tumors, both necessary for
accurate risk assessment, which is essential for successful
therapeutic management [1,13].
Rates of recurrence, either distant or local, are correlated with
various factors, the most important of which are pathological
stage and grade. A common site of recurrence after treatment
of UTUC is the bladder. Intravesical recurrence following RNU
is a common problem, with an incidence of nearly 20%-50%
[1]. In a meta-analysis (4057 participants) assessing the impact
of diagnostic URS prior to RNU, a strong correlation was found
between previous URS and development of intravesical
recurrence during follow-up after RNU (hazard ratio=1.53,
P<.001) [10]. Tumor location also plays a role in the choice of
therapy based on anatomic location [1,6,14].
Rationale for a Clinical Registry
Available clinical information on the management of UTUC
relies mainly on historical cohorts. Monocentric data from
merging international databases or population-based studies
have provided the highest level of evidence so far and are
challenging the standard management algorithms [15-17].
Although valuable, this type of information is prone to bias.
Patient selection criteria, attrition bias, and verification bias are
among the most frequent confounders in spite of efforts to adjust
for them. Even in large cohorts, confounding variables cannot
be completely corrected for. Although associations may be
observed, they rarely confirm causality and may have unknown
effects [18,19].
In an intent to increase the quality of evidence, systematic
reviews and meta-analysis have explored specific UTUC
outcomes of distinct treatment modalities as well as predictive
and prognostic factors [19-27]. Obviously, they provide insights
in the natural history of UTUC, but they are still the product of
a low-evidence report. Therefore, they do not result in strong
recommendations due to the flaws in accuracy and
generalizability [28].
Although randomized trials (RCTs) would provide sound
answers, the rarity of the condition prevents studies from
obtaining an adequately powered sample size for correct
comparison in a reasonable study time. The late onset and
comorbidity of the affected population will limit inclusion and
likely preclude generalizability of RCT results. In this scenario,
it is rational to rely on alternative study designs that allow rapid
data collection with inclusion of a large population with a
broader geographic and ethnic spectrum [29,30].
Clinical registries are defined as “a system that collects a defined
minimum data set from patients undergoing a particular
procedure, diagnosed with a disease or using the health care
resource” [29]. They are observational databases focusing on a
specific clinical condition, therapy, or population without
specific mandate approaches and are intended to reflect “real
world” practice in a large population. When properly designed
and executed, they serve to improve the quality of health care
and as hypothesis generators [29].
Very little is known about the prevalence of registries
worldwide. Overall, the interest has increased rapidly in the last
decade in countries such as the United States, Sweden, and the
United Kingdom, with more than 100 registries per country.
Whether named registries, quality registries, clinical databases,
clinical audits, or quality improvement programs, the medical
societies unanimously recognized their value in the clinical
research context [31,32].
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We hereby present the design of the Clinical Research Office
of the Endourology Society (CROES)-UTUC registry.
Objectives
Overall, the registry aims to provide a contemporary real-world
overview and generalizable comparative outcomes on the
incidence and management of UTUC across the globe. The
CROES-UTUC registry focusses primarily on incidence,
indications, treatment, and patient outcomes. When possible,
comparative clinical effectiveness of different interventions and
assessment of safety of these interventions will be performed.
The primary objective is to describe contemporary patterns of
presentation, practice, and treatment of UTUC according to
geographic characteristics.
The secondary objectives identified by the steering committee
during the design of the registry include several short- and
long-term comparative outcomes listed below:
• To assess the compliance with the current EAU guidelines
on UTUC recommendations
• To assess the validity of risk stratification, as recommended
by the current EAU guidelines on UTUC
• To assess the intra- and postoperative complications
stratified by type of treatment
• To determine the rates and type of recurrences (upper tract
and bladder/local or distant) as well as risk factors for
patients presenting with primary UTUC stratified by type
of treatment (kidney-sparing treatment vs radical
nephroureterectomy vs segmental ureterectomy), stage at
presentation, select clinicopathologic characteristics, and
gender
• To determine comparative overall survival stratified by
type of treatment and stage at presentation.
Methods
Study Design
This is an observational, international, multicenter, cohort study,
prospectively collecting clinical data on consecutive patients
with UTUC. The registry is set up by the CROES, and its design
follows the recommendations of the Agency for Healthcare
Research and Quality (US) of 2014 for design and use of patient
registries for scientific, clinical, and health policy purposes [29].
This registry collects clinical data on patients with UTUC,
irrespective of onset, location, or type of treatment. It enrolls
patients at the moment of their health care visits and includes
baseline information on demography, symptoms, risk factors,
and laboratory variables. Diagnostic procedures are captured
as well as management, treatment, and follow-up details (up to
5 years after inclusion). In summary, it captures patterns of
presentation, diagnostics, and treatment as well as short-, mid-,
and long-term oncological and functional outcomes. The
operational flow diagram design of the registry is provided in
Figure 1. Patients were not involved in the design of the registry.
Version 2 of the protocol was registered in September 2014 in
Clinical trials.gov (trial registration: NCT02281188). The data
and material for this study are available from CROES upon
request.
A steering committee composed of six international experts in
the field oversaw the design process and checked the structure
of the registry. Primary and secondary objectives were defined
before design and initiation of the registry. The different centers
have the opportunity to identify “ad hoc” secondary objectives
and propose studies across the duration of the study. The steering
committee will review the different study proposals; modify
the proposal, if necessary; and consequently approve or deny
them. Proposals will be handled according to chronological
submission.
Due to the amount of data and the opportunity for the centers
to propose studies, not all secondary objectives were predefined
prior to initiation of the registry. They will be identified “ad
hoc” by the participating centers or the steering committee
according to the data available at the time of study proposal.
We foresee that the large sample size will allow for comparative
studies on benefit of interventions, evaluation and definition of
risk factors for recurrence, as well as associations and
quasi-randomized outcomes comparisons.
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Figure 1. Operational flow diagram of the CROES-UTUC (Clinical Research Office of the Endourology Society for urothelial carcinomas of the upper
tract) registry. Colors indicate the different levels of data input, management, and output as well as the interaction directions among them. Green color
indicates external sources of information (participating centres); blue colour indicates central registry office tasks; pink/blue color indicates a combination
of centres and central office registry output. IRB: institutional review board.
Participant Characteristics
Adult patients (age≥18 years) suspected of having UTUC either
as primary onset or after previous bladder urothelial cancer
(during follow-up) and scheduled to undergo any type of
diagnostic instrumentation of the upper urinary tract or any
surgical treatment (ie, RNU, kidney sparing surgery by URS or
percutaneous treatment or segmental ureter or pelvic resection
with or without any other neoadjuvant, perioperative, or adjuvant
interventions) will be included in the registry. In line with the
design and objectives of a registry, the inclusion criteria are
broad, while the exclusion criteria are minimized.
No direct benefits or risk for patients are derived from the
participation in the registry. The registry data do not imply any
change in management policy or practice apart from the standard
practice in the respective centers at any moment of the
diagnostic and therapeutic follow-up processes.
Data Collection and Analysis
Data from all participating centers will be collected through
electronic case report forms by using an online data management
system (DMS). The DMS is a Web-based system, which makes
it convenient for participants worldwide to use, and multiple
users of the same institution can be connected to the same data.
The DMS is located and maintained at the CROES Office. A
more detailed overview of the CROES DMS is provided in
Multimedia Appendix 1 [33,34].
Local sites will fill out the electronic case report forms in the
DMS prospectively and continuously over time and at the
appropriate time. The correspondent local principal investigator
is responsible for the reliability of the data and for controlling
the accuracy of data. Patient data entered in the DMS was coded,
and according to the European General Data Protection
Regulation that went "into force" in May 2018, that data is
pseudonymized. This means that only the controller (principal
investigator responsible for the respective center) can link the
code to the patient for audit purposes and follow-up data
provision. The identity of the patients is not accessible through
the CROES-DMS.
The DMS provides detailed overview reports of included data
and runs queries to check for data inconsistencies and outlying
values in order to ensure a reliable high-quality dataset. To
minimize missing data, the CROES Office sends updates of the
database to the principal investigator and is responsible for
sending reminders to encourage provision of missing or
follow-up data. The managers of the CROES office are in charge
of monitoring the registry. Reports are regularly made to the
steering committee. Data inconsistencies will be addressed by
the local principal investigator, and decisions will be made by
the steering committee on a case-by-case scenario.
Essential data elements aim to capture the multiple dimensions
of the condition, from diagnosis to survival outcomes; baseline
characteristics; risk factors; imaging and clinical assessment;
management; complications up to 30 days after intervention;
and survival data at 1, 3, and 5 years.
Data variables included in the electronic case report forms are
categorized into six domains: general data, pretreatment
assessment, treatment, pathology results, postoperative course,
and follow-up. Each domain includes multiple variables.
All variables are defined, and they can be categorical (including
descriptive, eg, type of complication for rare complications) or
continuous. The variables collected include demographic and
clinical patient characteristics, risk factors and symptoms,
imaging and laboratory tests, treatment type, and pathological
and survival outcomes. The key variables are described in
Textbox 1.
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Textbox 1. Domains, key variables, and total number of variables in the UTUC-CROES registry.
• General data (number of variables=71)
• Patient demographics




• Pretreatment assessment (number of variables=80)
• Imaging (local, regional, and distant)
• Cystoscopy
• Cytology
• Clinical tumor, node, and metastasis stage
• Treatment data (number of variables=141)





• Pathological data (number of variables=44)
• Grade and Stage (2016 World Health Organization International Society of Urologic Pathologists)
• Pathological Stage
• Perioperative data (number of variables=29)
• Use of antibiotics
• Complications up to 30 days (number and type)
• Clavien-Dindo classification complications
• Use of intravesical instillation
• Indication for adjuvant therapy
• Follow-up (number of variables=76; 76 variables per follow-up domain (maximum 5-year follow-up). Maximum of 21 follow-up visits possible
in the data management system per patient.
• Survival status
• Presence of recurrence
• Location of recurrence
• Diagnostics performed
• Results of the diagnostics
• Total variables (number of variables=441)
As described in the operational flow diagram of the registry,
the CROES statisticians will perform statistical analysis after
data audit and data cleaning. The analysis will be performed
after identification of specific objectives and attaining study
approval from the steering committee.
Descriptive statistics will be used to summarize the data. Results
will be presented in tables reporting at least the number of
subjects, mean, SD, and minimum and maximum for continuous
data and the number of subjects and percentages for categorical
data. For testing, a significance level of 5% will be maintained,
and all tests will be two-sided.
All analyses will be carried out on available data, and
proportions of missing data will be reported. All analyses will
be performed using SPSS version 25 (IBM Corporation,
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Armonk, New York) or R studio (RStudio Team, Boston,
Massachusetts).
Multivariable analyses will be performed to assess possible
associations with geographical or ethnic differences and risk
factors for complications after surgery. The methodology will
address potential sources of bias. When necessary, sensitivity
analysis will be conducted. We will not use external data sources
for comparison unless they are considered to be of outmost
importance for specific objectives.
After closure of the primary inclusion process, an audit will be
planned. The audit will focus on data source verification of the
values of the identified critical variables and on internal
consistency by cross checking among exclusive variables.
Availability of Data
Individual centers have signed a data transfer agreement. The
centers are responsible for providing data and can use their own
data for individual publications upon request and authorization
of the steering committee of the registry.
The steering committee will revise and give final approval to
any paper derived from the data collected in the course of the
study and will determine authorship based on contribution on
any paper derived from this registry. Findings and reports
derived from this registry will be presented at international
urology and oncology conferences and published in
peer-reviewed journals. CROES will summarize the findings
on the Web by regular information letters [35].
Results
The registry was initiated in November 2014 and aims to recruit
up to 3000 patients in a 5-year period. The study has been
registered at the competent authority for observational studies.
Institutional review board approval was requested and judged
not necessary according to the Medical Research Involving
Human Subjects Act (date of resolution: October 15, 2014; ref
W14-273#14.17.329).
The study recruitment was initiated in November 2014. Data
collection started in December 2014 and as of submission of
this manuscript, 2451 patients from 125 centers from 37
countries have been included. Inclusion of patients will be closed
5 years after initiation of the registry. Quality checks are
performed centrally with continuous communication and
feedback with the centers to ensure accuracy. First results in
terms of descriptive outcomes, patterns of practice, and
compliance with the current guidelines are expected soon after
patient inclusion is closed. Mid- and long-term outcomes are
expected in the first trimester of 2020.
Discussion
Because prospective data are scarce, many unanswered questions
remain about the management and comparative outcomes of
UTUC. Conversely, the grade of recommendations is supported
by low evidence, although this fact does not always preclude a
strong recommendation in a disease with a low prevalence.
Besides the rapidly evolving technological field that impacts
diagnosis and treatment, several obstacles hinder the
implementation of a RCT on the subject [30]. The advanced
age of patients, limited availability of armamentarium, high rate
of comorbidities of the affected population, and undesired
outcomes of standard treatment are some of these obstacles. A
recent study showed that comorbidity is inversely associated
with being offered participation in clinical oncologic trials even
after adjusting for the effects of demographic and socioeconomic
factors [36]. Furthermore, it is unlikely that several RCTs may
provide recommendations that will fit the whole spectrum of
patients and various aspects of the disease. It is under these
conditions that outcomes derived from observational cohorts
or pragmatic clinical trials will be filling the gaps [37-39]. The
biggest clinical challenge in UTUC is the high rate of
overtreatment in patients who could be safely offered a
kidney-sparing approach as well as the high rate of
undertreatment in patients with invasive disease who need more
than RNU (ie, [neo]adjuvant systemic therapy to treat occult
metastasis).
In line with the definition of a clinical registry, the inclusion
criteria of our registry are broad, to capture real-world data on
presentation, diagnosis, treatment indication, and outcomes of
UTUC. In case of a disease with a low prevalence, registries
have a great potential in supporting clinical research and as a
source of future trials [29,37]. Registries face practical and
operational challenges [29,38,40]. Matters that may compromise
the functionality of the CROES-UTUC registry were taken into
account at the design phase.
Regarding the logistic organization, the data are centrally
collected in a standardized way; they are clinically oriented and
adequately frame the affected population. Furthermore, rapid
and regular communication and feedback between the central
management core of the registry and the participating centers
are provided. Regarding quality control, patient data are
anonymized and the CROES office monitors the data and sends
reminders to encourage the respective principal investigators
to ensure completeness and accuracy of essential data elements,
especially when missing data are detected. The audit process
of the data is independent from the steering committee and
participating centers. Secondary data quality checks, cleaning,
and analysis will be performed by professional statisticians.
Once these operational questions are addressed with satisfaction,
there are still challenges that may hinder the internal validity
of a registry as well as the attainment of reliable data [29,37].
Erroneous capture of patients’ information remains a potential
source of bias that is difficult to solve in any type of study,
especially in studies with retrospective designs. It is our
experience that proactive continuous auditing and checking
contradictory or exclusive variables minimizes this error,
although it is unknown to what extent. Confounding will be
considered for any of the planned and proposed studies under
clinical and statistical supervision, and information regarding
data transfer to the registry (manually or from electronic health
records) will be taken into account as possible sources of bias.
Differences exist in local practices and protocols as well as
regional variations in standard of care or access to care [37].
Although inherent to any multicentric registry and precisely
one of the outcomes to be captured, interpretation may be
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difficult. Therefore, efforts will be made to adjust for these
differences, with a thorough critical analysis. As any center can
participate independent of case volume or experience,
differences in volume outcomes may surface. These differences
may become important and potentially have a positive impact
in the quality of care and value-based health care parameters,
as highlighted in a recent systematic review [40].
In fact, clinical registries such as pragmatic clinical trials are a
valuable complement to RCTs [39] and continue to evolve as
a possible niche for RCTs, and incorporation of patient
participation becomes a point of reference for evidence-based
medicine [40-42]. Despite recognizing the subordinate level of
evidence of registry-generated data with respect to RCTs [39],
we strongly believe that this internationally prospective collected
data will be helpful in understanding the current scenario in
management of UTUC and will generate hypotheses to nurture
focused RCTs.
With all this in mind, we are aware that the large amount of
data collected may be a burden for the centers and that the
research output may be limited by missing data. As centers are
allowed and encouraged to propose different hypothesis-driven
studies, the steering committee together with the statisticians
will thoroughly examine the different proposals. The possibility
remains that some of the preliminary defined secondary
objectives may not be reached, while some others may turn out
to be feasible.
In conclusion, the CROES-UTUC registry is a powerful source
of information by compiling international clinical data on
real-world presentation and treatment of UTUC. The design
and logistics of the registry provide adequate operational flow,
functionality, and quality control and ensure transparency. An
effort is being made to minimize bias in data collection and
analysis by means of regular reminders and feedback. The
central management and the steering committee guarantee the
statistical and clinical support. Lastly, the implication of the
centers in proposing secondary objectives and authoring
different studies represents, in our view, an additional scientific
incentive.
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